Table 4.
Comparison of differences in prognostic indicators between drug groups
| Characteristics | No CCB/aspirin, n (%) | CCB and aspirin, n (%) | Aspirin without CCB, n (%) | CCB without Aspirin, n (%) | P value |
| n = 98 | n = 15 | n = 40 | n = 11 | ||
| Sex | |||||
| Male | 56 (57.1) | 5 (33.3) | 25 (62.5) | 8 (72.7) | 0.169 |
| Age (yr) | |||||
| < 60 | 39 (39.8) | 5 (33.3) | 8 (20.0) | 3 (27.3) | 0.157 |
| ≥ 60 | 59 (60.2) | 10 (66.7) | 32 (80.0) | 8 (72.7) | |
| Blood pressure status | |||||
| Hypertensive | 27 (27.6) | 13 (86.7) | 22 (55.0) | 11 (100.0) | 0.000 |
| Non-hypertensive | 71 (72.4) | 2 (13.3) | 18 (45.0) | 0 (0.0) | |
| BMI | |||||
| < 18.5 | 2 (2.0) | 0 (0) | 1 (2.5) | 0 (0.0) | 0.307 |
| 18.5-25 | 52 (53.1) | 5 (33.3) | 24 (60.0) | 3 (27.3) | |
| > 25 | 41 (41.8) | 9 (60.0) | 14 (35.0) | 8 (72.7) | |
| Adjuvant chemotherapy | |||||
| Received post-op | 69 (70.4) | 9 (60.0) | 23 (57.5) | 9 (81.8) | 0.333 |
| Not received | 24 (24.5) | 5 (33.3) | 13 (32.5) | 1 (9.1) | |
| CA19-9 | |||||
| < 47 | 27 (27.6) | 3 (20.0) | 9 (22.5) | 1 (9.1) | 0.437 |
| 47-1000 | 51 (52.0) | 7 (46.7) | 20 (50.0) | 7 (63.6) | |
| > 1000 | 8 (8.2) | 3 (20.0) | 6 (15.0) | 3 (27.3) | |
| ASA grade | |||||
| 1-2 | 81 (82.7) | 12 (80.0) | 22 (55.0) | 8 (72.7) | 0.008 |
| 3-4 | 17 (17.3) | 3 (20.0) | 18 (45.0) | 3 (27.3) | |
| Resection value | |||||
| R0 | 14 (14.3) | 6 (40.0) | 9 (22.5) | 5 (45.5) | 0.020 |
| R1 | 83 (84.7) | 9 (60.0) | 31 (77.5) | 6 (54.5) | |
| T status | |||||
| T1-2 | 3 (3.1) | 2 (13.3) | 1 (2.5) | 0 (0.0) | 0.199 |
| T3-4 | 95 (96.9) | 13 (86.7) | 39 (97.5) | 11 (100.0) | |
| N status | |||||
| N0 | 7 (7.1) | 3 (20.0) | 5 (12.5) | 0 (0.0) | 0.242 |
| N1 | 90 (91.8) | 12 (80) | 35 (87.5) | 11 (100.0) |
P-values were calculated using tests χ2 tests. CCB: Calcium channel blockers; ASA: American society of anaesthesiologists; BMI: Body mass index.